-
公开(公告)号：US06455035B1
公开(公告)日：2002-09-24
申请号：US09286033
申请日：1999-04-05
IPC分类号： A61K3818
CPC分类号： A61K38/1891 , Y10S514/885
摘要： The present invention provides for a method of decreasing or inhibiting vascular permeability and/or plasma leakage in a mammal comprising administering to the mammal a TIE-2 receptor activator. The invention also provides for a method of decreasing or inhibiting vascular permeability and/or plasma leakage in a mammal comprising administering to the mammal an Ang-2 inactivator such as an anti-Ang-2 neutralizing antibody.
摘要翻译： 本发明提供了降低或抑制哺乳动物血管通透性和/或血浆渗漏的方法，包括向哺乳动物施用TIE-2受体激活剂。 本发明还提供减少或抑制哺乳动物血管渗透性和/或血浆渗漏的方法，包括向哺乳动物施用Ang-2灭活剂，例如抗Ang-2中和抗体。
-
2.发明申请Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) 审中-公开通过管理特异性结合促血管生成素-2（Ang-2）的抗体治疗或预防疟疾的方法公开(公告)号：US20120189635A1
公开(公告)日：2012-07-26
申请号：US13417372
申请日：2012-03-12
IPC分类号： A61K39/395 , A61P33/06
CPC分类号： C07K16/22 , A61K31/513 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/412 , A61K2300/00
摘要： The present invention provides methods for treating or preventing malaria by administering to a patient in need thereof a pharmaceutical composition comprising an antibody that specifically binds human angiopoietin-2 (Ang-2).
摘要翻译： 本发明提供了治疗或预防疟疾的方法，其通过向有需要的患者施用包含特异性结合人血管生成素-2（Ang-2）的抗体的药物组合物。
-
公开(公告)号：US20110027286A1
公开(公告)日：2011-02-03
申请号：US12843905
申请日：2010-07-27
申请人： Gavin Thurston , Christopher Daly
发明人： Gavin Thurston , Christopher Daly
IPC分类号： A61K39/395 , C07K16/22 , A61P35/00 , A61P37/00 , A61P17/06
CPC分类号： C07K16/22 , A61K31/513 , A61K38/1866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
摘要翻译： 本发明提供了结合血管生成素-2（Ang-2）的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人Ang-2结合的完全人抗体。 本发明的抗体尤其用于治疗与一种或多种Ang-2生物学活性（包括血管生成）相关的疾病和病症。
-
4.发明申请公开(公告)号：US20080107648A1
公开(公告)日：2008-05-08
申请号：US11639894
申请日：2006-12-15
申请人： Irene Noguera , Gavin Thurston , Nicholas Gale , Eric Smith
发明人： Irene Noguera , Gavin Thurston , Nicholas Gale , Eric Smith
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： A61K39/0011 , A01K2267/0331 , C07K2319/30 , C12N2799/022 , C12N2799/027
摘要： A therapeutic method for inhibiting tumor development or growth, comprising administering an agent capable of inhibiting human delta-like ligand 4 (DII4) activity to a subject in need thereof. In one embodiment, the agent is an anti-DII4 antibody or antibody fragment capable of inhibiting the binding of DII4 to a Notch receptor. In another embodiment, the agent is a fusion protein comprising the extracellular domain of DII4 or a fragment or variant thereof, fused to a multimerizing component such as an Fc domain. The method of the invention is useful for inhibiting tumor growth, particularly in tumors which are not responsive to other therapeutic agents.
摘要翻译： 一种抑制肿瘤发展或生长的治疗方法，包括向有需要的受试者施用能够抑制人类δ-配体4（DII4）活性的药剂。 在一个实施方案中，所述试剂是能够抑制DII4与Notch受体结合的抗DII4抗体或抗体片段。 在另一个实施方案中，所述试剂是包含融合到多聚化组分如Fc结构域的DII4的细胞外结构域或其片段或变体的融合蛋白。 本发明的方法可用于抑制肿瘤生长，特别是在对其它治疗剂无反应的肿瘤中。
-
公开(公告)号：US08987420B2
公开(公告)日：2015-03-24
申请号：US12843905
申请日：2010-07-27
申请人： Gavin Thurston , Christopher Daly
发明人： Gavin Thurston , Christopher Daly
IPC分类号： C07K16/22 , A61K39/395 , A61K31/513 , A61K38/18 , A61K45/06 , A61K39/00
CPC分类号： C07K16/22 , A61K31/513 , A61K38/1866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
摘要翻译： 本发明提供了结合血管生成素-2（Ang-2）的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人Ang-2结合的完全人抗体。 本发明的抗体尤其用于治疗与一种或多种Ang-2生物学活性（包括血管生成）相关的疾病和病症。
-
公开(公告)号：US20110150905A1
公开(公告)日：2011-06-23
申请号：US13034761
申请日：2011-02-25
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
摘要翻译： 本发明提供通过向有需要的受试者施用特异性结合人类δ样配体4（hDll4）并阻断hDll4的人抗体或其片段来治疗，改善或抑制肿瘤生长，癌症或病理性血管发生的方法 与Notch受体结合。 本发明的抗hDll4抗体或其片段通过表面等离振子共振测得的具有500pM以下的KD的高亲和力。
-
公开(公告)号：US20090017035A1
公开(公告)日：2009-01-15
申请号：US12245392
申请日：2008-10-03
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of 300 pM or better, as measured by surface plasmon resonance.
摘要翻译： 分离的人抗体或人抗体的片段，其特异性结合人类δ样配体4（hDll4）并阻断hDll4与Notch受体的结合。 通过表面等离振子共振测量，人抗hDll4抗体或抗体片段以300pM或更好的亲和力结合hDll4。
-
公开(公告)号：US20060134121A1
公开(公告)日：2006-06-22
申请号：US11264243
申请日：2005-10-31
申请人： Gavin Thurston , Nicholas Gale , Irene Noguera
发明人： Gavin Thurston , Nicholas Gale , Irene Noguera
IPC分类号： A61K48/00 , G01N33/574 , A61K39/395 , C07K16/30
CPC分类号： C07K14/705 , C07K2319/30 , G01N33/6893 , G01N2800/32
摘要： Methods for screening for agents capable of inhibiting Dll4 are provided, as well as therapeutic methods for treating Dll4-mediated conditions. More specifically, methods are provided for identifying agents capable of inhibiting blood vessel growth and formation, such as antibodies to human DLL4.
摘要翻译： 提供了能够抑制Dll4的药物筛选的方法，以及用于治疗Dll4介导的病症的治疗方法。 更具体地，提供了用于鉴定能够抑制血管生长和形成的药剂的方法，例如针对人类DLL4的抗体。
-
9.发明授权公开(公告)号：US08518887B2
公开(公告)日：2013-08-27
申请号：US12823680
申请日：2010-06-25
CPC分类号： C07K16/18 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.
摘要翻译： 本发明提供了通过施用Dll4拮抗剂，特别是Dll4抗体及其与人Dll4特异性结合的片段的组合以及化学治疗剂来治疗各种类型的癌症/肿瘤的方法。 与单独使用任一试剂的治疗相比，这种联合疗法表现出协同效应。 因此，本发明的方法对于通过能够降低有效剂量而对由单独的任一药物治疗所需的高剂量引起的副作用的耐受性低的癌症患者特别有益。 还提供了含有Dll4拮抗剂和化学治疗剂的药物组合物和试剂盒。
-
公开(公告)号：US07919593B2
公开(公告)日：2011-04-05
申请号：US12002245
申请日：2007-12-14
IPC分类号： C07K16/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of ≦500 pM, as measured by surface plasmon resonance.
摘要翻译： 分离的人抗体或人抗体的片段，其特异性结合人类δ样配体4（hDll4）并阻断hDll4与Notch受体的结合。 通过表面等离振子共振测量，人抗hDll4抗体或抗体片段以＆nlE; 500pM的亲和力结合hDll4。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.028 秒)
